Personalized test tracks cancer relapse
نویسندگان
چکیده
منابع مشابه
Human Cancer Modeling: Recapitulating Tumor Heterogeneity Towards Personalized Medicine
Despite diagnostic, preventive and therapeutic advances, growing incidence of cancer and high rate of mortality among patients affected by specific cancer types indicate current clinical measures are not ideally useful in eradicating cancer. Chemoresistance and subsequent disease relapse are believed to be mainly driven by the cell-molecular heterogeneity of human tumors that necessitates perso...
متن کاملHuman Cancer Modeling: Recapitulating Tumor Heterogeneity Towards Personalized Medicine
Despite diagnostic, preventive and therapeutic advances, growing incidence of cancer and high rate of mortality among patients affected by specific cancer types indicate current clinical measures are not ideally useful in eradicating cancer. Chemoresistance and subsequent disease relapse are believed to be mainly driven by the cell-molecular heterogeneity of human tumors that necessitates perso...
متن کاملpharmacogenetics and personalized medicine in pancreatic cancer
pancreatic cancer (pc) is a progressive, fatal disease with a high degree of malignancy. more than 40000 peoplediefrom this cancer annually in the united states. as a multifactorial condition, pc has a complex nature, and there are several genes and signalingpathwaysimplicated in pc pathogenesis and progression. there are diffèrent mutations in master genesincludingtumorsuppressors and oncogene...
متن کاملCancer genetics: Two tracks but one race?
The protein p16 was initially identified as an inhibitor of cyclin-dependent kinase (Cdk) activity — specifically, it was found to bind and inhibit cyclin D–Cdk4 [1]. This inhibition prevents phosphorylation of the retinoblastoma product (Rb) and progression from G1 to S phases of the cell cycle [2,3]. Previous observations that the Rb gene is frequently inactivated, and the cyclin D gene ampli...
متن کاملDevelopment Tracks for Cancer Prevention Markers
We provide a general framework for describing various roles for biomarkers in cancer prevention research (early detection, surrogate endpoint, and cohort identification for primary prevention) and the phases in their evaluation.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature
سال: 2017
ISSN: 0028-0836,1476-4687
DOI: 10.1038/545417a